Accordingly, the results of our analysis show that YY1 is considerably upregulated in HNSC, breast, bladder, and lung cancers (LUSC and LUAD), while PEBP1 is significantly downregulated in all kidney and lung cancer subtypes, as well as in LIHC, HNSC, and STAD. Here, PEBP1 is linked to lung carcinoma.